Combined nelfinavir and cisplatin treatment promotes inflammatory signaling and immunogenic cell death in ovarian cancer cells
En palabras de los autores
Platinum (Pt) based chemotherapy remains central to ovarian cancer (OC) treatment, but recurrent disease frequently develops Pt resistance and responds poorly to immune checkpoint inhibitors. Immunogenic cell death (ICD) links tumor cell killing to antitumor immunity; however, cisplatin (CDDP), widely used in OC, is an incomplete ICD inducer. We previously demonstrated that the HIV protease inhibitor nelfinavir (NFV) enhances CDDP induced OC cell death and promotes a lytic, pyroptosis associated phenotype. Here, we investigated whether NFV enhances the immunogenic consequences of CDDP treatment. RNA seq analysis of OC cells treated with CDDP, NFV, or their combination revealed enrichment of interferon (IFN) associated, cytoplasmic DNA sensing, inflammatory chemokine, and antigen presentation pathways following NFV containing treatments. NFV alone and CDDP plus NFV reduced mature Lamin A abundance and increased extranuclear double stranded DNA accumulation. Cytosolic fractionation and droplet digital PCR demonstrated increased cytosolic TP53 DNA, particularly following combined treatment. CDDP plus NFV increased STING and TBK1 phosphorylation, supporting engagement of the cGAS STING TBK1 signaling pathway. The combination enhanced release of inflammatory and ICD associated mediators, including HMGB1, IL18, and IFNbeta. Importantly, vaccination with CDDP plus NFV-treated murine ID8 OC cells protected immunocompetent female mice against subsequent live ID8 cell challenge, reducing tumor incidence and burden. In contrast, ID8 cells killed by freeze thaw-induced accidental necrosis provided no comparable protection. Collectively, these findings indicate that NFV enhances the immunogenic consequences of CDDP induced OC cell death, potentially involving cytoplasmic DNA accumulation and STING TBK1 signaling, and promotes protective antitumor immunity in vivo. These results support further investigation of NFV as a repurposed partner for Pt based chemotherapy and its potential combination with immunotherapy in OC.
Apareció: jueves, 19 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.